Cerebral small vessel disease (SVD) describes a set of pathologies affecting the smallest blood vessels in the brain. SVD contributes to up to a fifth of ischemic and hemorrhagic strokes en is the main vascular cause of dementia. On MRI, SVD is marked by different types of lesions, including white matter abnormalities, and small infarcts and hemorrhages. Recent studies indicate that SVD develops slowly over the years, starting presumably decades before the typical MRI lesions become apparent. High blood pressure plays an important role in the development of SVD MRI lesions. However, it remains unclear exactly how hypertension leads to vascular pathology. To gain more insight into how hypertension leads to SVD it is important to study mechanisms in individuals (largely) free of SVD, that is before midlife. Therefore, the investigators aim to examine abnormalities in brain (micro) structure and vascular function in young patients with hypertension. Furthermore, the investigators aim to determine the effects of blood pressure increase and subsequent blood pressure reduction during a period of withdrawal and restart of blood pressure lowering drugs on brain (micro)structure and vascular function.
Study Type
OBSERVATIONAL
Enrollment
130
To determine if high blood pressure is caused by an overproduction of aldosterone in the adrenal gland (i.e. primary hyperaldosteronism), the plasma aldosterone/renin ratio (ARR) can be determined. Because many common hypertensive drugs are known to interfere with this ratio, patients often have to discontinue drugs prior to screening or switch to drugs that are known not to affect ARR (i.e. doxazosin, verapamil, diltiazem, hydralazine). Drugs have to be stopped for at least four weeks (for mineralocorticoid receptor antagonists) or two weeks (for diuretics, Angiotensin Converting Enzyme (ACE) inhibitors, Angiotensin Receptor Blockers (ARBs)). This often leads to a temporary increase in blood pressure. After diagnostics are completed, medication is adjusted accordingly and blood pressure levels drop again.
RadboudUMC
Nijmegen, Netherlands
RECRUITINGStandard neuroimaging markers of SVD, assessed using STRIVE criteria
This includes white matter hyperintensity volumes, lacunes, microbleeds, DWI+ positive lesions.
Time frame: Baseline, four weeks after antihypertensive drug withdrawal, after 1-4 months when blood pressure is stable, 1 year later.
DCE-MRI outcomes
Leakage rate (Ki)
Time frame: Baseline, four weeks after antihypertensive drug withdrawal, after 1-4 months when blood pressure is stable, 1 year later.
DCE-MRI outcomes
Volume fraction (Vl)
Time frame: Baseline, four weeks after antihypertensive drug withdrawal, after 1-4 months when blood pressure is stable, 1 year later.
DTI outcomes
Fractional Anisotropy (FA)
Time frame: Baseline, four weeks after antihypertensive drug withdrawal, after 1-4 months when blood pressure is stable, 1 year later.
DTI outcomes
Mean Diffusivity (MD)
Time frame: Baseline, four weeks after antihypertensive drug withdrawal, after 1-4 months when blood pressure is stable, 1 year later.
DTI outcomes
Peak Skeleton ofMean diffusivity (PSMD)
Time frame: Baseline, four weeks after antihypertensive drug withdrawal, after 1-4 months when blood pressure is stable, 1 year later.
Intravoxel Incoherent Motion outcomes
Parenchimal Diffusivity (D)
Time frame: Baseline, four weeks after antihypertensive drug withdrawal, after 1-4 months when blood pressure is stable, 1 year later.
Intravoxel Incoherent Motion outcomes
Perfusion fraction (F)
Time frame: Baseline, four weeks after antihypertensive drug withdrawal, after 1-4 months when blood pressure is stable, 1 year later.
Intravoxel Incoherent Motion outcomes
Microvascular perfusion (fD\*)
Time frame: Baseline, four weeks after antihypertensive drug withdrawal, after 1-4 months when blood pressure is stable, 1 year later.
Resting state fMRI
Functional connectivity
Time frame: Baseline, four weeks after antihypertensive drug withdrawal, after 1-4 months when blood pressure is stable, 1 year later.
Cognition
Cognitive functioning is assessed using a 60-min cognitive assessment covering six domains: processing speed, attention, executive functioning, verbal memory, working memory and psychomotor functioning.
Time frame: Baseline, four weeks after antihypertensive drug withdrawal, after 1-4 months when blood pressure is stable, 1 year later.
Motor functioning
Motor functioning is assessed using a 6-m walking test (in seconds) and the Timed Up \& Go test (in seconds)
Time frame: Baseline, four weeks after antihypertensive drug withdrawal, after 1-4 months when blood pressure is stable, 1 year later.
Blood markers
This includes circulating markers of inflammation, including cytokines and chemokines, in mmol/l measured in blood.
Time frame: Four weeks after antihypertensive drug withdrawal and after 1-4 months when blood pressure is stable.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.